Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310901 · ClinicalTrials.gov registry record · Phase 1
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
A Phase 1 study of Obese But Otherwise Healthy Participants, sponsored by Corbus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 15
- Study locations
NCT07310901 is a Phase 1 study of Obese But Otherwise Healthy Participants that is actively recruiting participants, run by Corbus Pharmaceuticals. The registered enrollment target is 252 participants. The trial reports 15 study locations across 10 states.
The verdict
NCT07310901, a Phase 1 study of Obese But Otherwise Healthy Participants, is actively recruiting participants, sponsored by Corbus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRB-913
Study Locations (15)
Florida
- Accel Research Sites - DeLand
- Tampa Bay Medical Research - Largo
- Quotient Sciences - Miami
New York
- Neurobehavioral Research - Cedarhurst
- Rochester Clinical Research - Rochester
Ohio
- Medpace Clinical Pharmacology - Cincinnati
- Velocity Clinical Research - Cleveland
Texas
- Velocity Clinical Research - Dallas
- Flourish Research - San Antonio
Alabama
- Central Alabama Research - Birmingham
Arizona
- Arizona Clinical Trials - Chandler
California
- Prospective Research Innovations - Rancho Cucamonga
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07310901
The ClinicalTrials.gov registry entry for NCT07310901 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obese But Otherwise Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07310901 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT07310901 about?
NCT07310901 is a clinical study titled "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity". This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects...
What is the current status of trial NCT07310901?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2025-12-04. Estimated completion is 2026-07-31.
What conditions does trial NCT07310901 study?
This clinical trial studies the following conditions: Obese But Otherwise Healthy Participants.
What interventions are being tested in trial NCT07310901?
The interventions under investigation include: Placebo (DRUG), CRB-913 (DRUG).
Who is sponsoring clinical trial NCT07310901?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310901 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obese But Otherwise Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.